Home › US companies › Revvity

Revvity

RVTY · NYSE · Laboratory Analytical Instruments
Insider buys (12 months)
0
Insider sales (12 months)
$6M
8-K reports (12 months)
5
Tracked investors holding
1

At a glance

Revvity reported 2025 revenue of $2.86B, up 3.7% from $2.76B in 2024. Over 4 years since 2021 ($3.83B), that is a decline of about 7.1% a year. Operating margin was 12.5%, down from 32.9% in 2021. Revenue peaked in 2021 at $3.83B.

In the last 12 months 7 insiders reported 0 open-market purchases and 10 sales ($6M). 9 of the sales were made under pre-arranged 10b5-1 plans. The largest was a sale of $2.6M by Please See Remarks Prahlad R. Singh on Feb 6, 2026.

Revvity filed 5 current reports (Form 8-K) in the last 12 months, most often for results of operations (4), bylaws or fiscal year change (1) and shareholder vote results (1).

1 of the 20 investors tracked here held Revvity at the last quarter end, worth $2.7M combined. It is the largest weight for Bridgewater Associates (0% of its portfolio). Reduced: Bridgewater Associates.

Annual results

2021
Revenue $3.83B
Op. $1.26B
2022
Revenue $3.31B
Op. $742.7M
2023
Revenue $2.75B
Op. $300.6M
2024
Revenue $2.76B
Op. $346.7M
2025
Revenue $2.86B
Op. $356.6M
RevenueOperating income (or net income)SEC XBRL annual filings, fiscal years mapped to calendar years
Year20212022202320242025
Net income$943.2M$569.2M$693.1M$270.4M$241.2M
Diluted EPS$8.08$4.50$5.55$2.20$2.07
Dividend per share-$0.28$0.28$0.28$0.28

Fiscal year ends Dec 29 · incorporated in MA

Tracked investors holding (13F)

Bridgewater AssociatesReduced$2.7M · 0.0% · held 2 quarters

Weight is the share of each investor's portfolio, as of the quarter end.

Current reports (8-K, last 12 months)

Insider open-market trades (last 12 months)

Source: SEC EDGAR. How figures are combined